Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment for Pivotal Clinical Trial of AXPAXLI in Wet AMD

BEDFORD - Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

Related Keywords

United States ,Donald Notman ,Chris Brinzey ,Antony Mattessich ,Ocular Therapeutix Inc ,Agreement Modification For The Company ,Exchange Commission ,Nasdaq ,Market Scope Retinal Pharmaceuticals ,Drug Administration ,Special Protocol Assessment ,Agreement Modification ,Scope Retinal Pharmaceuticals Market Report ,Private Securities Litigation Reform Act ,Risk Factor ,News Publishing ,Markets ,